Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study.

Clinical pharmacology and therapeutics - 1 May 2024

Fukui Rika, Noda Satoshi, Ikeda Yoshito, Sawayama Yuichi, Terada Tomohiro, Nakagawa Yoshihisa, Morita Shin-Ya

Abstract excerpt

Proton pump inhibitors (PPIs) have recently been reported to be linked with nephrotoxicity. PPIs are metabolized mainly or partly by cytochrome P450 2C19 (CYP2C19). However, the relationship between CYP2C19 genetic polymorphism and PPI-induced nephrotoxicity is unclear. In this study, we aimed to analyze the association between the time of occurrence of renal injury by PPIs, including lansoprazole, esomeprazole,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney

Share to Lansoprazole

Share to Proton Pump Inhibitors

Share to Pyrroles

Share to Rabeprazole

Share to Sulfonamides

Source

Identifiers

PMID: 38258325
DOI: 10.1002/cpt.3183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study.PMID 38258325Read ↗

Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.Semantic proximity Read ↗

Proton Pump Inhibitor Use, CYP2C19 genotypes, and Subsequent Incidence of Chronic Kidney DiseaseSemantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Incidence of drug interaction when using proton pump inhibitor and warfarin according to cytochrome P450 2C19 (CYP2C19) genotype in Japanese.Semantic proximity Read ↗

The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.Semantic proximity Read ↗

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.Semantic proximity Read ↗

CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.Semantic proximity Read ↗

Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.Semantic proximity Read ↗

CYP2C19 genotypes and osteoporotic fractures in long-term users of proton pump inhibitors: A hospital-based study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.